Stockreport

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Genmab A/S - American Depositary Shares  (GMAB) 
PDF Updated data from the Phase 1/2 RAINFOLâ„¢-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two [Read more]